Researchers locate overactive genes in triple-negative breast cancer
Jun 2, 2011
New research published in the Journal of Clinical Investigation shows a series of genes that are overactive and may contribute to a triple-negative breast cancer, according to a new report from the Daily Mail.
"The discovery of these targets will rapidly lead to clinical trials with the hope of achieving one of the first specific therapies for triple-negative breast cancers," said Kornelia Polyak, a breast cancer geneticist.
Triple-negative breast cancer is notoriously hard to treat and is also one of the more deadly forms of the illness. The name of the disease comes from the fact that the tumor cells do not have receptors to oestrogen, progesterone and HER2 protein.
More than 200,000 women were diagnosed with breast cancer during 2010, according to the American Cancer Society. One in eight women in the U.S. are diagnosed with breast cancer at some point in her life, according to BreastCancer.org.